#1179 Zoledronic acid (Zol) significantly reduces skeletal-related events(SREs) in patients with bone metastases from solid tumors. (excerpts) L. Rosen, D. Gordon, S Tchekmeyian, V. Hirsh, R.Yanagihara, RE Coleman, D Reitsma, J Seaman. Univ of California, Los Angeles,; US Oncology, San Antonio, TX; Pacific Shores Medical Group, Long Beach, CA; McGill University, Montreal, QC, Canada;Yorkshire Cancer Research, Weston Park Hospital, Sheffield, UK; Novartis Pharmaceutical, E. Hanover, NJ The efficacy of Zol, a new nitrogen-containing bisphosphonate, was investigated in a randomized, double-blind, placebo-controlled, phase III trial for the treatment of bone metastasis from solid tumors other than breast or prostate cancer. A total of 773 patients were randomized in a 3-arm trial (Zol 4 mg, Zol 8 mg, or placebo via a 15-minute infusion) every 3 weeks for 9 months. Of these patients, 51% had lung cancer (primary non-small cell) and the remainder had other solid tumors (including renal, unknown primary, and bladder cancer). Results: In this trial, 4 mg Zol significantly decreased the proportion of patients with at least 1 skeletal-related event (SRE) and significantly prolonged the time to first SRE There is no significant difference between groups in bone pain (51% Zol versus 59% placebo), nausea (46% versus 34%), anemia (37% versus 33%), or vomiting (36% versus 29%) This study is the first to demonstrate the efficacy of a bisphosphonate in the treatment of metastasis from a wide variety of solid tumors. Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.